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ABSTRACT | A novel flavin adenine dinucleotide-dependent amine oxidase that is secreted by the 
kidney, circulates in the blood, and modulates cardiac function and systemic blood pressure has recently 
been discovered. Renalase appears to be a hormone that metabolizes catecholamines, and its discovery 
will facilitate our understanding of sympathetic regulation. 
 
It isn’t every day that a new renal hormone is 
discovered. First, there was renin. Then came 
erythropoietin. The realization that the kidney is 
responsible for the final step in the production of 
active vitamin D led to the identification of a third 
hormone, calcitriol. The kidney also produces 
various prostaglandins and other products that 
may have substantial systemic effects. 
Recently published work by Xu et al. employs a 
“tour de force” approach to give us a new renal 
hormone, “renalase” [6]. To find novel renal 
proteins, the authors applied a series of selection 
criteria to the complete collection of clones 
published by the Mammalian Gene Collection 
Project. First, they selected proteins with less than 
20% sequence homology to known proteins. They 
also focused on proteins containing signal 
peptide sequences, which are key for protein 
export (of a hormone for instance). They excluded 
proteins that had transmembrane domains; the 
typical secreted protein lacks these. Next, 
Northern blot analysis was done for each of the 
114 candidate genes thus identified. One clone 
(MGC12474) showed a robust preferential renal 
expression with lower expression in heart, skeletal 
muscle, and liver. The longest open reading frame 
encoded a novel protein of 342 amino acids that 
they termed renalase. In human kidney, renalase 
was present in the glomeruli and proximal 
tubules, while in the heart the enzyme was 
associated with cardiomyocytes. 
The investigators generated a glutathione 
synthase-renalase recombinant protein in E. coli 
that they successfully purified. They observed that 
when flavin adenine dinucleotide (FAD) was 
omitted during protein synthesis, the synthetic 
renalase had no oxidase activity. Thus, renalase is 
FAD dependent. Renalase had a 13.2% amino acid 
identity with monoamine oxidase A (MAO-A), 
another FAD-dependent enzyme. MAO-A and 
MAO-B are mitochondrial outer membrane bound 
flavoproteins that catalyze the oxidative 
deamination of neurotransmitters and biogenic 
amines. A number of mechanism-based inhibitors 
have been developed for clinical use as 
antidepressants and as neuroprotective drugs. The 
three-dimensional crystal structure of MAO-B has 
been prepared; that for MAO-A should follow 
shortly. The amino acid identity of the two 
proteins is 70%. 
The physiological function of MAO-A and MAO-B 
was elucidated by the study of Norrie disease. The 
three genes encoding NDP, MAO-A, and MAO-B lie 
adjacent to one another on the X chromosome. A 
contiguous chromosomal deletion of the three 
genes causes severe mental retardation, seizures, 
hypotonic crises, impaired somatic growth, and 
altered peripheral autonomic fucion. Loss of MAO-
A and MAO-B is reflected neurochemically by 
severely reduced plasma and urinary 
concentrations of catecholamine-deaminated 
metabolites, including dihydroxyphenyl glycol, 
the deaminated metabolite of norepinephrine and 
epinephrine. An X-linked selective MAO-A 
deficiency has also been described, whose 
neurochemical phenotype closely resembles that 
in patients with the contiguous gene syndrome. 
The genes encoding MAO-A and MAO-B have also 
been deleted in the mouse [4]. MAO-A gene-
deleted mice have increased circulating serotonin, 
norepinephrine, and dopamine, whereas MAO-B 
gene-deleted mice show increased 
phenylethylamine levels. Both MAO-detected 
strains were subjected to exogenous stress 
reaction tests and showed an increased response. 
Based on the above information, the investigators 
pursued the notion that renalase might be 
important in amine oxidation. After identifying an 
amino-oxidase domain in the predicted amino 
acid sequence, a host of probable substrates were 
lined up for testing. Renalase gobbled up 
dopamine, epinephrine, and noreipnephrine in 
that order of preference. However, neither MAO-A 
nor MAO-B inhibitors (pargyline and clorgyline, 
respectively) could block renalase. The authors 
then purified renalase from human urine. The 
material again metabolized catecholamines with 
the same substrate specificity. Anti-renalase 
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antibody blocked the effects. 
The authors then tested renalase in rats. Sprague-
Dawley rats given intravenous renalase decreased 
their blood pressures by 25%; the effect dissipated 
within minutes. Heart rate decreased accordingly, 
as did cardiac contractility. The effects were dose 
dependent. The cardiovascular effects described 
by the authors were dramatic and convincing. The 
animals behaved as if they had been suddenly 
subjected to a massive α and β adrenoceptor 
blockade. As a matter of fact, such an experiment 
would have been a nice positive control. 
Given these tantalizing basic findings, what is the 
evidence that a catecholamine-catabolizing 
enzyme produced in the kidney might be 
clinically relevant? Norepinephrine-containing 
renal sympathetic nerves innervate all segments 
of the kidney [2]. Neural regulation has a major 
effect on renal sodium and volume reabsorption, 
which in turn influences blood pressure. The 
tubular effects are independent of 
vasoconstriction. Neural activity also largely 
regulates renin release. There are three renal 
neuroeffectors: the vasculature, the 
juxtaglomerular granular cells, and the renal 
tubules. The renal neural regulation is modulated 
by renal afferent neural signals. However, the 
notion that the kidney might produce a hormone 
influencing catecholamines and their disposition 
was not anticipated. 
Xu et al. [6] found that renalase is virtually absent 
in dialysis patients, although normal subjects have 
the material in abundance. Dialysis patients have 
increased sympathetic tone. Their circulating 
catecholamines are higher than nondialysis 
control subjects. Furthermore, sympathetic 
activity can be measured at the nerve level with 
microneurography in human subjects. The 
technique involves the placement of a very fine 
tungsten needle into the peroneal nerve, where 
the nerve wraps around the fibula at the knee. 
Dialysis patients are generally hypertensive and 
have increased sympathetic nerve traffic [1]. 
However, when bilateral nephrectomy is 
performed in dialysis patients, their hypertension 
generally goes away. Moreover, their muscle 
sympathetic nerve activity is reduced to normal or 
even lower levels. Conceivably, the increased 
sympathetic tone in dialysis patients is 
attributable to renalase deficiency. Nevertheless, 
the presence of diseased kidneys must also supply 
a signal since bilateral nephrectomy obviously 
cannot restore renalase. 
The authors show that dopamine is effectively 
degraded by renalase. However, dopamine is 
associated with lower blood pressure and 
decreased cardiovascular risk. Felder et al. (2002) 
[3] found that in human essential hypertension, 
single-nucleotide polymorphisms of a G protein-
coupled receptor kinase, GRK4γ, increased G 
protein-coupled receptor kinase (GRK) activity and 
caused serine phosphorylation and uncoupling of 
the dopamine D(1) receptor from its G 
protein/effector enzyme complex in the renal 
proximal tubule. The effect was verified in 
transfected Chinese hamster ovary cells. Their 
findings would suggest that diminished 
dopaminergic tone would increase blood pressure 
and cardiovascular risk. Renalase could have an 
adverse effect on blood pressure by lowering 
dopamine, particularly in the kidney. 
There are distinct differences between MAO-A and 
renalase. Renalase is secreted into the circulation 
while MAO-A and MAO-B are confined to the 
intracellular mitochondrial membrane. The 
authors indicate that amine-oxidase activity has 
been measured in human plasma previously. The 
vascular adhesion protein 1 (VAP-1) is believed to 
mediate that activity. The VAP-1 protein is a 
copper-containing semicarbazide-sensitive amine 
oxidase that is secreted by vascular smooth 
muscle cells, adipocytes, and endothelial cells [5]. 
However, the substrate specificity of VAP-1 is very 
distinct from renalase. 
The discovery of renalase will potentially 
contribute to our understanding of increased 
cardiovascular risk in patients with chronic renal 
disease. Cardiovascular risk correlates with 
sympathetic tone and circulating norepinephrine 
concentrations. Since renalase is made within the 
kidney, possibly its major function resides within 
the organ. Renal sympathetic nerve activity 
performs the fine-tuning of cardiovascular and 
blood pressure regulation. A potentially beneficial 
therapeutic effect for patients with hypertension 
or heart failure would be the blockade of α1-
adrenergic receptors [2]. By metabolizing 
norepinephrine within the kidney, renalase could 
perform that function. The discovery of renalase 
will surely usher in a host of additional 
investigations into the mechanisms by which 
renalase may act and the role it plays. Most likely, 
the actions of renalase will be important to 
cardiovascular health in general and should 
extend far beyond patients with reduced renal 
function. 
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